Chinese yam alpha-glucan as well as preparation method and application thereof

Through the isolation and preparation of ɑ-glucan from yam, the problem that existing methods for treating ulcerative colitis cannot achieve mucosal healing, and the regulation of cytokines and growth factors can be used to inhibit intestinal epithelial cell apoptosis and promote mucosal membranes. The repair effect provides new drugs for the treatment of ulcerative colitis.

CN118930683APending Publication Date: 2024-11-12GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410244032.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-03-04
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing treatment methods for ulcerative colitis cannot effectively achieve mucosal healing, resulting in long-term surgical intervention in patients, and existing drugs can only provide temporary relief, and there is a lack of effective new drugs to treat ulcerative colitis.

Method used

Isolate and prepare an ɑ-glucan from yam. By pretreatment, anion exchange column chromatography separation and gel column chromatography purification methods, the obtained yam ɑ-glucan is only from (1→4)-ɑ -D-Glcp chain composition, with a theoretical molecular weight range of 5000-25000Da, used to treat ulcerative colitis.

Benefits of technology

Yam ɑ-glucan can regulate cytokines and growth factors, inhibit apoptosis of intestinal epithelial cells, reconstruct tight junctions, promote the repair of mucosal damage in ulcerative colitis, and have obvious immune regulation effects. It is used to prepare and treat ulcerative colon. Inflammation drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930683A_ABST
    Figure CN118930683A_ABST
Patent Text Reader

Abstract

The invention discloses Chinese yam alpha-glucan as well as a preparation method and application thereof. The Chinese yam alpha-glucan is separated and purified from Chinese yam crude polysaccharide, and the structure of the Chinese yam alpha-glucan is 1, 4-glucosidic bond connected alpha-D-glucan. Animal experiment results show that the Chinese yam alpha-glucan provided by the invention can promote DSS-induced mouse ulcerative colitis mucosal injury repair through the ways of regulating and controlling multiple cell factors and growth factors, inhibiting intestinal epithelial cell apoptosis, reconstructing tight junction integrity and the like. Meanwhile, an in-vitro cell experiment shows that the compound has an obvious immune regulation effect. Therefore, the Chinese yam alpha-glucan provided by the invention can be used for treating ulcerative colitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicines and relates to yam α-glucan, a preparation method and application thereof. Background Art

[0002] In recent years, non-starch polysaccharides from plants have become an important bioactive natural product. At present, a variety of α-D-glucans have been isolated and identified from a variety of plants and fungi. For example, Raveendran et al. isolated a (1→4)-α-D-glucan with a molecular weight of 550 kDa from Tinospora cordifolia; Schepetkin et al. isolated a glycogen-like α-glucan from Lentinula edodes mycelium; and a 13 kDa α-glucan was also reported from Cnidium monnieri. These α-D-glucans have the function of activating NK cells, T cells, and B cells, can enhance the phagocytosis of macrophages, and stimulate the secretion of cytokines. In addition, some other types of α-glucans have been shown to promote the proliferation of mouse spleen lymphocytes and protect mice from acute liver injury by reducing serum alanine aminotransferase, aspartate aminotransferase, malondialdehyde levels, and increasing the activity of total superoxide dismutase in the liver. At the same time, α-D-glucan isolated from Panax notoginseng has been shown to inhibit the growth of S-180 tumor cells by increasing the number of leukocytes and lymphocytes in mice and inducing apoptosis of tumor cells.

[0003] Yam polysaccharide is considered to be one of the main functional components of yam, with biological activities such as antioxidant, anti-tumor, antibacterial, anti-inflammatory, immunomodulatory and hypoglycemic. At present, a variety of yam polysaccharides with different molecular weights, different monosaccharide compositions, and different acidity and alkalinity have been separated and purified. The structure and pharmacological activity of yam polysaccharides vary greatly due to different extraction, separation and purification methods. Zhao et al. used different methods to purify four yam polysaccharides with different molecular weights and uronic acid contents. Among them, yam polysaccharides with lower molecular weight and higher uronic acid content have stronger antioxidant activity (Zhao C, Xia L, Jing M, et al. The effect of different extraction techniques on property and bioactivity of polysaccharides from Dioscorea hemsleyi [J]. International Journal of Biological Macromolecules, 2017, 102: 847-856.). At present, α-glucan from yam has not been reported.

[0004] Inflammatory bowel disease (IBD) is a gastrointestinal disease in which genetically susceptible people often show uncontrolled chronic inflammation when exposed to environmental antigens. Ulcerative colitis (UC) is one of the most common types of IBD, and its incidence is increasing worldwide. Although the pathogenesis of UC has not been fully elucidated, it is generally believed to be the result of the combined effects of multiple factors such as genetics, environment, and intestinal microorganisms.

[0005] In the current clinical treatment of UC, the goal of treatment is often to achieve clinical remission in patients. However, due to the mismatch between clinical symptoms and the course of UC disease (such as asymptomatic patients showing strong inflammatory responses in their blood and intestinal tissues), treatment plans aimed at clinical remission are gradually being replaced by therapies aimed at achieving mucosal healing. Studies have shown that achieving intestinal mucosal healing in UC patients can effectively maintain remission, reduce hospitalization rates, surgical rates, and improve quality of life. Although current treatments include anti-inflammatory drugs such as aminosalicylates and glucocorticoids, as well as immunosuppressants (such as azathioprine and infliximab), they all play a certain role in mucosal healing, but these drugs can only induce or maintain short-term remission, and 45% of UC patients still require surgical intervention in the later stages. Therefore, new drugs are needed to treat UC disease and achieve mucosal healing. Summary of the invention

[0006] The object of the present invention is to provide a yam α-glucan to solve at least one of the above technical problems.

[0007] Another object of the present invention is to provide a method for preparing yam ɑ-glucan to solve at least one of the above technical problems.

[0008] Another object of the present invention is to provide the use of yam α-glucan in the preparation of a medicament for treating ulcerative colitis.

[0009] According to one aspect of the present invention, a yam ɑ-glucan isolated from yam is provided, which is composed of (1→4)-ɑ-D-Glcp chains and is a ɑ-D-glucan with a theoretical molecular weight range of 5000-25000Da.

[0010] According to another aspect of the present invention, there is provided a method for preparing the above-mentioned yam α-glucan, comprising the following steps:

[0011] S1: Pretreatment: Degreasing, depigmenting and deproteinizing crude yam polysaccharide, dialyzing the obtained polysaccharide aqueous solution, and drying to obtain yam polysaccharide;

[0012] S2: Anion exchange column chromatography separation: The yam polysaccharide is prepared into a yam polysaccharide aqueous solution, and then separated by anion exchange column, and the eluate obtained by eluting with ultrapure water is collected and dried to obtain yam secondary polysaccharides;

[0013] S3: Gel column chromatography purification: The yam secondary polysaccharide is prepared into a yam secondary polysaccharide aqueous solution, and then separated using a Superdex 200prep grade gel column and eluted with ultrapure water. During the elution process, the molecular weight of the sugar in the eluate is tracked and detected, and the eluate with a molecular weight of 5000-25000Da is collected and dried to obtain yam α-glucan.

[0014] A yam ɑ-glucan can be separated from yam crude polysaccharide by the separation and purification method provided by the present invention. The monosaccharide composition of the prepared yam ɑ-glucan is analyzed, and it is proved that the yam ɑ-glucan prepared by the present invention is only composed of glucose. The yam ɑ-glucan prepared by the present invention is further structurally analyzed by infrared analysis, nuclear magnetic resonance analysis and other methods, and it is verified that the structure of the yam ɑ-glucan prepared by the present invention is ɑ-D-glucan connected by 1,4-glycosidic bonds.

[0015] In some embodiments, in step S1, taking crude yam polysaccharide for defatting, depigmenting and deproteinizing treatment may include the following steps:

[0016] (1) Extracting crude yam polysaccharide with a solvent obtained by mixing methanol and chloroform in a volume ratio of 8:1 at 80° C. and reflux extracting for 24 hours, removing the solvent, and drying to obtain crude yam polysaccharide I; the solid-liquid ratio of crude yam polysaccharide to solvent is 1:(5-12) g / mL;

[0017] (2) extracting the yam crude polysaccharide I with ethanol having a mass fraction of not less than 95% by reflux for 3 times, each time for 60 minutes, removing the ethanol, and drying to obtain the yam crude polysaccharide II; the solid-liquid ratio of the yam crude polysaccharide I to ethanol is 1:10 g / mL;

[0018] (3) The crude yam polysaccharide II was deproteinized by the Sevag method to obtain a polysaccharide aqueous solution.

[0019] In some embodiments, the solid-liquid ratio of yam crude polysaccharide to solvent can be 1:10 g / mL. The amount of degreasing reagent added directly affects the degreasing effect. Too little will result in incomplete degreasing, and too much will result in waste of reagents.

[0020] In some embodiments, 95% ethanol is used to reflux extract the yam crude polysaccharide I. The mass fraction of ethanol used for reflux extraction of the yam crude polysaccharide I is less than 95%, which may result in incomplete removal of pigments and loss of some low molecular weight polysaccharides.

[0021] In some embodiments, the method for deproteinizing yam crude polysaccharide II by Sevag method can be specifically as follows: prepare yam crude polysaccharide II into a 50 mg / mL aqueous solution, add a mixture of chloroform and n-butanol in a volume ratio of 4:1 at a volume ratio of 5:1, mix well, centrifuge, take the upper polysaccharide aqueous solution, and repeat the above steps until the protein layer is no longer obvious.

[0022] After the crude yam polysaccharide is defatted, depigmented and deproteinized, the obtained product has poor solubility and still contains a lot of impurities, and further dialysis treatment is required. In some embodiments, the dialysis treatment can specifically be: using a dialysis bag with a molecular weight cutoff of 3500Da to dialyze the polysaccharide aqueous solution.

[0023] In some embodiments, the anion exchange column may be DEAE Sephadex Fast Flow.

[0024] In some embodiments, in step S2, the concentration of the yam polysaccharide aqueous solution can be 100-150 mg / mL. When using a DEAE Sephadex Fast Flow (1.6 cm×16 cm) anion exchange column to separate yam polysaccharides, a sample load of less than 100 mg / mL affects the efficiency, and a sample load of more than 150 mg / mL may result in incomplete separation.

[0025] In some embodiments, in step S2, the concentration of the yam polysaccharide aqueous solution can be 100 mg / mL.

[0026] In some embodiments, in step S3, the concentration of the yam secondary polysaccharide aqueous solution can be 50-100 mg / mL. When the yam secondary polysaccharide is loaded on a Superdex 200prep grade (1.6 cm×80 cm) gel column for separation and purification, the loading amount is preferably controlled at 50-100 mg to avoid affecting the elution effect of the gel column.

[0027] In some embodiments, in step S3, the concentration of the yam secondary polysaccharide aqueous solution can be 50 mg / mL.

[0028] In some embodiments, the method for tracking and detecting the molecular weight of sugars in the eluate during the elution process can be selected from one of the phenol-sulfuric acid method and high performance gel permeation chromatography (HPGPC).

[0029] In some embodiments, the elution process can be performed by BioCore TM The molecular weight of the sugars in the eluate was tracked and detected using a SEC-150 gel chromatography column.

[0030] Animal experiments have shown that in the constructed mouse ulcerative colitis mucosal recovery model, the yam ɑ-glucan provided by the present invention can promote the repair of DSS-induced mouse ulcerative colitis mucosal damage by regulating multiple cytokines, growth factors, inhibiting intestinal epithelial cell apoptosis, and reconstructing tight junction integrity. At the same time, in vitro experiments have shown that it has obvious immunomodulatory effects. Therefore, the yam ɑ-glucan provided by the present invention or a pharmaceutical composition comprising the yam ɑ-glucan provided by the present invention and one or more pharmaceutically acceptable excipients can be used to prepare a drug for the treatment of ulcerative colitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 is the elution curve of CYP separated by DEAE Sephadex Fast Flow column;

[0032] Figure 2 The chromatograms of the eluates from tubes 33-39 (A) and 40-44 (B) were detected by HPGPC method;

[0033] Figure 3 The graph is a molecular weight distribution spectrum of dextran standards (molecular weight of 5kDa, 12kDa and 25kDa) detected by HPGPC method;

[0034] Figure 4 BioCore TM Overlay of molecular weight distribution of CYP1-A and CYP1 detected by SEC-150 gel column;

[0035] Figure 5 This is the liquid chromatogram of the PMP derivatization method combined with HPLC to detect the monosaccharide composition and glucose of CYP1-A;

[0036] Figure 6 The chromatogram of the mixed standard solution detected by PMP derivatization method combined with HPLC;

[0037] Figure 7 is the infrared spectrum of CYP1-A;

[0038] Figure 8 CYP1-A 1 H NMR spectrum;

[0039] Fig. 9 CYP1-A 13 C NMR spectrum;

[0040] Fig.10 The effect of CYP1-A on the weight change rate of mice;

[0041] Fig.11 The effect of CYP1-A on the DAI index of mice;

[0042] Fig.12 The effect of CYP1-A on the colon length of mice;

[0043] Fig.13 The effect of CYP1-A on the histomorphology of mouse colon;

[0044] Fig.14 The effect of CYP1-A on Ki-67 expression in mouse colon tissue;

[0045] Fig.15 The effect of CYP1-A on the level of TNF-ɑ in mouse plasma;

[0046] Fig.16 The effect of CYP1-A on the expression of genes related to mucosal healing (MH);

[0047] Fig.17 The effect of CYP1-A on the expression of Cleaved-Caspase-3 protein in mouse colon tissue;

[0048] Fig.18 The effect of CYP1-A on the expression of ZO-1 and Claudin-2 proteins in mouse colon tissue;

[0049] Fig.19 The effect of CYP1-A on the activity of RAW 264.7 cells;

[0050] Fig. 20 The effect of CYP1-A on NO secretion in RAW 264.7 cells;

[0051] Fig.21 CYP1-A promotes the secretion of IL-6 and TNF-ɑ in RAW 264.7 cells;

[0052] Fig. 22 The effect of CYP1-A on the expression of IL-6, TNF-ɑ, IL-1β, and iNOS mRNA in RAW 264.7 cells;

[0053] Fig.23 This is the effect of CYP1-A on the expression of p-p65 protein in RAW 264.7 cells. DETAILED DESCRIPTION

[0054] The present invention is further described in detail below in conjunction with the embodiments. The examples are only for explanation and are not intended to limit the present invention in any way. Unless otherwise specified, the raw materials and reagents used in the examples are conventional products that can be obtained commercially; the experimental methods in the examples without specifying the specific conditions are conventional methods and conventional conditions well known in the art.

[0055] Example 1 Preparation of yam α-glucan

[0056] S1. Preprocessing

[0057] (1) Weigh 80 g of crude yam polysaccharide (purchased from Shanghai Yuanye Biotechnology Co., Ltd., purity ≥ 70%), place in a reflux extraction device, add 800 mL of a solvent obtained by mixing methanol and chloroform in a volume ratio of 8:1, extract in a water bath (80° C.) for 24 h, and after cooling, use a vacuum pump filtration device to drain the solvent. After filtration, fully evaporate the solvent in a fume hood at room temperature.

[0058] (2) Collect the yam crude polysaccharide I obtained after evaporation, place it in a round-bottom flask, add 95% ethanol at a solid-liquid ratio of 1:10, reflux and extract for 1 hour, the solid-liquid ratio unit is g / mL, and repeat this step 3 times. After filtration, the solvent is fully evaporated in a fume hood at room temperature to obtain defatted and depigmented yam crude polysaccharide powder (i.e., yam crude polysaccharide II, hereinafter referred to as "CYP-P1").

[0059] (3) CYP-P1 was deproteinized using the classic Sevag method, specifically: yam crude polysaccharide II was prepared into a 50 mg / mL aqueous solution, 35 mL was taken and placed in a 50 mL centrifuge tube, 7 mL of chloroform-n-butanol (pre-prepared into a mixed solution with a volume ratio of 4:1) was added, and the mixture was gently inverted up and down, centrifuged at 3000 rpm for 6 minutes, and the upper polysaccharide aqueous solution was aspirated, and the above operation was repeated until the protein layer was not obvious. The treated polysaccharide aqueous solution was dialyzed through a dialysis bag (molecular weight cutoff of 3500 Da) and freeze-dried to obtain yam polysaccharide (hereinafter referred to as "CYP").

[0060] S2, anion exchange column chromatography separation

[0061] Weigh 100 mg of yam polysaccharide (CYP), dissolve in 1 mL of ultrapure water, centrifuge, load onto DEAE Sephadex Fast Flow (1.6 cm × 16 cm), elute with 45 mL of ultrapure water, 0.05 M NaCl, and 0.2 M NaCl in sequence, collect the eluate, 3 mL per tube. Use the phenol-sulfuric acid method to detect the absorbance of the collected solution in each tube at 490 nm, and draw an elution curve, such as Figure 1 According to the elution curve, after freeze-drying the eluate, the ultrapure water elution fraction (neutral polysaccharide, i.e., yam secondary polysaccharide, hereinafter referred to as "CYP1"), 0.05M NaCl fraction (hereinafter referred to as "CYP2") and 0.2M NaCl fraction (CYP3 hereinafter referred to as "CYP3") were obtained.

[0062] S3, gel column chromatography purification

[0063] Weigh 50 mg of CYP1, dissolve in 1 mL of ultrapure water, filter through a 0.45 μm water filter, and load onto a Superdex 200prep grade (1.6 cm × 80 cm) gel column. Elute with ultrapure water at a flow rate of 1 mL min -1 The automatic collector collects one tube every 10 minutes and passes through BioCore TM The SEC-150 gel chromatography column was used to track the sugar distribution. The results are as follows: Figure 2 As shown. Figure 2 The results show that as the tube number increases, the molecular weight of the polysaccharide decreases gradually. The results are shown in Figure 2. Figure 3 As shown, the retention time of dextran (5kDa) is 19.63min, the retention time of dextran (12kDa) is 17.78min, and the peak time of dextran (25kDa) is 15.07min. Therefore, the eluates of tube numbers 33-39 were combined and freeze-dried to prepare yam polysaccharide (hereinafter referred to as "CYP1-A"). Theoretically, the molecular weight of CYP1-A should be between 5000-25000Da.

[0064] Experimental Example 1: CYP1-A structural identification

[0065] 1.1. Relative molecular weight determination

[0066] Chromatographic conditions: BioCore TM SEC-150 (7.8 mm × 300 mm, 5 μm) gel chromatography column; column temperature 30 °C; RID temperature 40 °C; mobile phase ultrapure water; flow rate 0.5 mL min -1 ; Injection volume 20 μL; Chromatographic time 40 min. Prepare the dextran series standards into 1 mg·mL -1 The aqueous solution was filtered with a 0.45 μm microporous filter and analyzed under the above chromatographic conditions. A linear curve was drawn with the peak time obtained as the horizontal axis and the logarithm of the relative molecular mass as the vertical axis, and the relative molecular weight of CYP1-A was calculated according to the regression equation.

[0067] BioCore TM The standard curve of dextran measured by SEC-150 is y=-0.1506x+6.6929, R 2 =0.9754. After calculation, the relative molecular weight of CYP1-A is 23.82 kDa. Figure 4 The superimposed spectra of CYP1-A and CYP1 are shown. CYP1-A can be considered as a polysaccharide component that has intercepted a portion of CYP1. The molecular weight range of CYP1 is relatively wide, but the intercepted CYP1-A component remains within the appropriate molecular weight range.

[0068] 1.2 Analysis of monosaccharide composition of CYP1-A

[0069] The monosaccharide molecules after hydrolysis were modified by 1-phenyl-3-methyl-5-pyrazolone (PMP) derivatization method, and the resulting derivatives were presented by high performance liquid chromatography (HPLC) spectroscopy. This method can be simultaneously applied to the analysis of monosaccharide composition of various forms of monosaccharides (neutral, acidic and basic) and complex polysaccharides.

[0070] Liquid phase conditions: Eclipse Plus C18 (4.6 mm × 250 mm); mobile phase: 0.1 M phosphate buffer (the buffer system has a pH of 6.8, weighing 8.66 g of dipotassium hydrogen phosphate and 6.85 g of potassium dihydrogen phosphate, dissolved in 1 L of ultrapure water, filtered through a 0.22 μm filter membrane)-acetonitrile (80:20, v / v); detection wavelength of 245 nm; column temperature of 30 °C, flow rate of 1 mL min -1 ; Injection volume 20μL; Elution time 40min.

[0071] Preparation of CYP1-A polysaccharide sample solution: Weigh 5 mg of CYP1-A polysaccharide powder and place it in a microwave synthesis tube, add 3 mL of 2M TFA (trifluoroacetic acid), and react at 120°C for 3 hours in a microwave synthesizer. After the reaction is fully completed, add 5 times the volume of methanol, decompress and spin dry, repeat the operation 5 times, wait until the trifluoroacetic acid is completely removed, then add 1 mL of 0.3M sodium hydroxide solution and 1 mL of 0.5M PMP-methanol solution in sequence, and react in a 70°C water bath for 2 hours. After cooling, add 0.3M hydrochloric acid solution (1 mL) and mix well to neutralize, then extract three times with 20 mL of chloroform, and after the upper aqueous phase passes through a 0.22μm filter head, inject and analyze.

[0072] Liquid phase spectrum of CYP1-A and glucose Figure 5 The liquid phase spectrum of the mixed standard solution is shown in Figure 6 As shown. Figure 6 The results showed that the CYP1-A chromatogram showed a single peak composition after excluding the interference of the solvent peak. By comparing with the monosaccharide standard and mixed standard solution spectra, the peak was identified as glucose.

[0073] 1.3 Infrared analysis

[0074] Take a small amount of CYP1-A polysaccharide powder and use an infrared spectrometer at 4000-400 cm -1 Scan within the band, record and export the infrared spectrum, such as Figure 7 shown.

[0075] In the infrared spectrum, 3307.3cm -1 、2928.1cm-1 The two absorption peaks represent OH stretching vibration and C 13 -H 1 Telescopic. At 1644.8cm -1 、1426.5cm -1 The absorption peaks at 1200-1000cm correspond to δ(HOH) and δ(OH). -1 Three characteristic absorptions within the range (1151.9, 1081.9, 1014.8 cm -1 ) indicates that the monosaccharide configuration is pyranose. 933.13cm -1 The absorption peak at 840.0 cm further confirms the existence of pyranose D-Glc. -1 The absorption peak at indicates that CYP1-A is α-D-glucan.

[0076] 1.4 Nuclear Magnetic Resonance Analysis

[0077] Weigh 30 mg of CYP1-A polysaccharide sample, place in a 1.5 mL EP tube, add 700 μL of D 2 O, vortexed and dissolved, filtered through a 0.45 μm aqueous filter, and then transferred into a nuclear magnetic resonance tube. The one-dimensional nuclear magnetic resonance spectrum of CYP1-A ( 1 H NMR, 13 C NMR) for data acquisition and analysis. Due to the large molecular weight of the polysaccharide sample, the acquisition time was set to 20 times the normal acquisition time.

[0078] From CYP1-A 1 H NMR ( Figure 8 ) observed that there were two resonance signal peaks in the anomeric hydrogen region. Based on the signals δ5.41ppm and δ4.98ppm, CYP1-A was judged to be α-glycoside-glucan, which was consistent with the results of infrared spectrum analysis. 13 C NMR ( Fig. 9 ), two anomeric carbon signals were observed at δ99.72ppm and δ99.55ppm. By comparing with the literature data, δ5.41ppm and δ99.72ppm were attributed to (1→4)-ɑ-D-Glcp. δ4.98ppm and δ98.70ppm were attributed to Glcp(1→.

[0079] Experimental Example 2: Yam α-glucan promotes mucosal recovery of dextran sulfate sodium (DSS)-induced ulcerative colitis in mice

[0080] During the experiment, IBM SPSS 20.0 statistical software and GraphPad Prism 8.0.2 software were used to analyze the data and draw statistical graphs. Data are presented as mean ± standard deviation. If the data obeyed the normal distribution and the variance was homogeneous, one-way analysis of variance was used, and the Bonferroni test was used for multiple comparisons; if the data did not meet the variance homogeneity, Dunnett's 3 T3 test was used for statistical analysis. All tests were two-sided, and P < 0.05 indicated statistical significance.

[0081] 2.1 Experimental groups and drug administration

[0082] Fifty BALB / c mice (male, SPF, 18-22g) were randomly divided into 5 groups, with 10 mice in each group. A, normal group; B, model group; C, DSS+CYP group; D, DSS+CYP2 group; E, DSS+CYP1-A group. The experimental period was 7 days. In the first 6 days, the mice in the normal group drank distilled water freely, and the mice in other groups drank 3% DSS aqueous solution through a ball drinking fountain. At the same time, the mice in the drug-treated groups (C, D, and E) were gavaged with the corresponding yam polysaccharide solution (concentration of 40 mg·mL) at 0.1 mL / 10 g (v / w). -1 ). After the administration on the 6th day, the 3% DSS solution was replaced with distilled water for the mice to drink freely, and the mice in each group were fasted for 12 hours. On the 7th day, the mice were anesthetized, killed, and dissected for samples.

[0083] 2.2 Effect of CYP1-A on the weight change rate and DAI index of mice

[0084] During the experiment, the diet, drinking water, and weight changes of the mice were recorded every day, and the mental state, blood in stool, and stool hardness of the mice were observed. The scoring criteria for the disease activity index (DAI) of mice are shown in Table 1.

[0085] Table 1 DAI scoring criteria

[0086] Score Body weight loss (%) Bleeding (in stool) Diarrhea 0 <2% No bleed Normal 1 ≥2-≤5% Weak hemoccult Softer stool 2 ≥5-≤10% Visible blood Uniformed stool 3 ≥10-≤15% Fresh rectal Watery stool 4 ≥15% - -

[0087] Days 1 to 6 are the acute inflammatory phase induced by the DSS modeling agent; days 6-7 are divided into the recovery phase. The weight rate of mice on the first day is used as the basis (100%), and statistical analysis is performed and the weight change rate of mice in the following 6 days is plotted. The results are shown in Fig.10 And as shown in Table 2.

[0088] Acute inflammation period: The weight of mice in the model group increased on the 2nd and 3rd days, but dropped sharply on the 5th and 6th days, which was statistically different from that of the normal group (P<0.001). On the 5th and 6th days, there was a significant difference between the CYP1-A administration group and the DSS model group (P<0.05), indicating that CYP1-A can resist the weight loss induced by the DSS modeling agent.

[0089] Recovery period: Due to fasting, the weight of mice decreased significantly on day 7. On day 7, the weight change rate of mice in the model group was significantly different from that in the DSS+CYP1-A group (P<0.01), indicating that CYP1-A can restore the weight of mice to a certain extent.

[0090] Table 2 Effect of CYP1-A on the weight change rate of mice in each group ( n=10)

[0091]

[0092]

[0093] Note: DSS group was compared with Normal group ( # P<0.05, ## P<0.01, ### P<0.001); DSS+CYP1-A group was compared with DSS group ( * P<0.05, ** P<0.01, *** P<0.001).

[0094] Effect of CYP1-A on DAI index in mice Fig.11 As shown in the figure, compared with the normal group, the DAI index in the DSS model group was significantly increased (P<0.001), and the DAI score value could be significantly reduced after the administration of CYP1-A (P<0.01).

[0095] 2.3 Effect of CYP1-A on colon length

[0096] After the mice were anesthetized and killed, the colon tissues were removed and the length of the mice's colon was measured.

[0097] The results are as follows Fig.12 As shown in the figure, compared with the normal group, the colon length of the DSS group was significantly shortened (P<0.001). After CYP1-A treatment, the colon length of mice was observed to increase, indicating that yam polysaccharides can restore the DSS-induced shortening of colon length to a certain extent.

[0098] 2.4 Effects of CYP1-A on Colonic Histomorphology

[0099] About 1 cm of tissue was cut from the distal third of the colon, fixed with 4% paraformaldehyde for 24 hours, embedded in paraffin, and sliced ​​(5 μm thick). The tissue sections were processed according to the HE standard operating procedures and histopathological analysis was performed under an optical microscope.

[0100] The results are as follows Fig.13 As shown in the figure, in the normal group, the intestinal epithelial cells of mice were neatly arranged with few damages; the glands and substrate crypts were orderly arranged and had normal morphology; the mucosa and mucosal layer had no inflammatory lesions. However, in the DSS model group, the intestinal epithelium was almost completely detached, and numerous inflammatory cells were observed in the mucosal layer, with a few distributed in the submucosal layer. At the same time, the number of crypts was significantly reduced, the morphology was irregular, and the length was short. In the DSS+CYP1-A group, a few inflammatory infiltrations were observed, the crypts at the bottom of the mucosa were partially missing, and no inflammatory lesions were observed in the submucosal layer. This indicates that CYP1-A can alleviate the colon pathological damage caused by DSS to a certain extent.

[0101] 2.5 Effect of CYP1-A on Ki-67 expression in colon tissue

[0102] The detailed operation steps of Ki-67 immunohistochemistry experiment are as follows:

[0103] (1) Dewaxing tissue sections: dewaxing in xylene for 15 min, repeated 3 times; dewaxing in gradient ethanol solutions for 5 min each; finally, rinsing in distilled water until hydrated.

[0104] (2) Antigen repair: Place the tissue sections in a repair box containing EDTA antigen repair solution, boil over medium heat for 8 minutes, then turn off the heat, keep warm for 8 minutes, and heat over medium-low heat for 7 minutes. During this period, avoid excessive evaporation of the repair solution to prevent dry sections. After cooling, wash the slides with PBS for 5 minutes, and repeat 3 times.

[0105] (3) Blocking endogenous peroxidase (EGPO): The sections were incubated in 3% hydrogen peroxide for 25 min (room temperature and away from light), and then washed with PBS three times, each time for 5 min.

[0106] (4) Blocking: Add one drop of 3% BSA into the tissue circle and block for 30 minutes (room temperature).

[0107] (5) Incubation with primary antibody: Gently shake off the blocking solution, add primary antibody PBS solution (Ki-67, 1:200), and incubate in a 4°C refrigerator for 12 h.

[0108] (6) Incubation with secondary antibody: Wash the slides three times with PBS, 5 min each time, gently shake off the residual liquid on the slides, add HRP-labeled goat anti-rabbit IgG, and incubate at room temperature for 50 min.

[0109] (7) DAB color development: Repeat the PBS washing step. Add freshly prepared DAB color development solution and observe the color change under a microscope. When brown-yellow color appears, quickly rinse the slide with distilled water to stop color development.

[0110] (8) Re-staining of cell nuclei: Stain with hematoxylin for 3 min, rinse with water, add hematoxylin differentiation solution for a few seconds, rinse with distilled water, add hematoxylin bluing solution to bluing, and rinse with water.

[0111] (9) Dehydration and sealing: The sections were dehydrated with gradient ethanol solution until transparent, air-dried, and sealed with neutral gum.

[0112] (10) Collect images under a microscope and analyze and process them. Cell nuclei are stained blue, and positive expression is brown-yellow.

[0113] The results are as follows Fig.14 As shown, the expression of Ki-67+ in the colon tissue of mice in the normal group was low. In the model group, due to the severe damage of the intestinal epithelial layer, mucosal layer, and crypts, only a small amount of Ki-67+ expression was observed in the cell nuclei around the remaining crypt tissue. In the DSS+CYP1-A group, Ki-67+ expression was obvious in the cell nuclei near the crypts. In normal colon tissue, the proliferation and apoptosis of the intestinal epithelium are strictly regulated by mechanisms. Within a few hours to a few days after the mucosal epithelium is damaged, colon epithelial cells begin to proliferate rapidly, so intestinal epithelial cell proliferation is considered to be an important feature of mucosal repair. The results of Ki-67 immunohistochemistry showed that CYP1-A can enhance the proliferation of intestinal epithelial cells, thereby promoting mucosal healing. In addition, the degree of mucosal healing can be reflected by the percentage of intact crypts in the colon tissue. The more intact crypts there are, the better the mucosal recovery. Fig.14 It can be found that in the DSS+CYP1-A group, the substrate crypts of the mouse colon tissue were arranged in an orderly manner and had complete morphology.

[0114] 2.6. Detection of TNF-ɑ in mouse plasma

[0115] The mouse abdominal aorta blood was collected using a disposable vacuum blood collection tube containing antithrombin. The blood was centrifuged at 3000 rpm for 15 min at 4°C, and the supernatant was collected and transferred to a clean EP tube. The TNF-ɑ content in mouse plasma was detected according to the operating instructions of the TNF-ɑ kit.

[0116] The results are shown in Table 3 and Fig.15 As shown. Although there was no statistical difference in the statistical analysis results of each group (P>0.05), it can be observed that TNF-ɑ has a certain trend of change in each group. Compared with the normal group, the TNF-ɑ content in the plasma of mice in the DSS group was reduced, and CYP1-A administration could increase the TNF-ɑ level in the plasma of mice.

[0117] Table 3 Effect of CYP1-A on TNF-ɑ levels in mouse plasma ( n=6)

[0118] Group <![CDATA[TNF-α content in mouse plasma (pg·mL -1 )]]> Normal 215.79±70.82 DSS 126.54±33.02P=0.122 DSS+CYP 172.12±51.09P=1.000 DSS+CYP1-A 165.67±65.04P=1.000 DSS+CYP2 197.69±60.186P=0.198

[0119] Note: DSS group was compared with Normal group ( # P<0.05, ## P<0.01, ### P<0.001); DSS+CYP1-A group was compared with DSS group ( * P<0.05, ** P<0.01, *** P < 0.001), and the P values ​​are listed in the table.

[0120] 2.7 Effect of CYP1-A on the expression of genes related to mucosal healing (MH)

[0121] Weigh about 20 mg of colon tissue sample into a 1.5 mL EP tube. Add 1 mL Trizol reagent and 2 magnetic beads, and crush the tissue with an automatic homogenizer at 4 ° C (60mHZ, 5 times, 1 min / time). After centrifugation, transfer 200 μL of supernatant to a new EP tube, add 200 μL of chloroform, mix by inversion 20 times, and let stand for 5 minutes. After centrifugation, aspirate 400 μL of the upper aqueous phase, add an equal volume of isopropanol, gently invert and mix 20 times, and let stand at room temperature for 10 minutes. Centrifuge again, discard the supernatant, add 1 mL of pre-cooled 75% ethanol (prepared with DEPC water), centrifuge at 8000rpm for 10 minutes, aspirate the solution, retain the bottom precipitate, air-dry at room temperature for 10 minutes, and add 20 μL of DEPC water to dissolve the RNA after the white RNA precipitate becomes transparent. Subsequently, RNA was purified by lithium chloride method, RNA concentration was determined by Nanodrop2000 ultra-micro UV spectrophotometer, reverse transcription was performed by Evo M-MLV reverse transcription kit II, and amplification was performed by Perfect StartGreen q PCR Super Mix kit. -ΔΔCT The relative expression fold of the target gene was calculated by the method. The relevant primer sequences are shown in Table 4.

[0122] Table 4 Related primer sequences

[0123]

[0124] The experimental results are shown in Table 5 and Fig.16As shown in the results, after DSS modeling, the expression of TNF-ɑ in the colon tissue of mice decreased, and after CYP1-A intervention, the expression of TNF-ɑ increased. Compared with the normal group, the expression of IL-1β gene in the model group was significantly decreased (P<0.01), and the expression of IL-1β in the CYP1-A treatment group was increased compared with the model group. The expression of IL-6 mRNA in the colon tissue of mice in the DSS modeling group was downregulated, and after CYP1-A treatment, the expression of IL-6 gene increased compared with the model group. Compared with the normal group, the expression of TGF-1β gene in the DSS model group was significantly decreased, and CYP1-A could increase the expression of TGF-1β in the colon tissue of mice. The expression of MMP-9 and Plaur mRNA in the DSS model group was lower than that in the normal group, and CYP1-A treatment could increase their expression, although there was no statistical difference (P>0.05). In summary, CYP1-A treatment can reverse the DSS-induced decrease in the expression levels of TNF-ɑ, IL-1β, IL-6, TGF-1β, MMP-9, and Plaur genes in colon tissue, among which the effect on TGF-1β was the most significant (compared with the model group, the expression increased by nearly 8 times).

[0125] Table 5 Effects of yam polysaccharides on the expression of IL-6, TNF-ɑ, IL-1β, TGF-1β, MMP-9 and Plaur mRNA in colon tissue ( n=5)

[0126] Group TNF-α IL-1β IL-6 TGF-1β MMP-9 Plaur Normal 1.08±0.48 1.03±0.29 1.43±0.83 1.36±1.16 1.19±0.69 0.98±0.73 DSS 0.28±0.13 <![CDATA[0.35±0.13 ## ]]> 0.29±0.04 0.07±0.03 0.58±0.41 0.31±0.17 DSS+CYP 0.47±0.13 0.78±0.24 0.98±0.68 1.58±0.60 1.06±0.51 0.42±0.18 DSS+CYP2 0.99±0.15 0.71±0.25 0.61±0.26 0.89±0.31 0.86±0.32 1.00±0.45 DSS+CYP1-A 0.45±0.26 0.88±0.42 0.71±0.24 0.55±0.49 0.72±0.36 0.56±0.16

[0127] Note: DSS group was compared with Normal group ( # P<0.05, ## P<0.01, ### P<0.001); DSS+CYP1-A group was compared with DSS group ( * P<0.05, ** P<0.01, *** P<0.001).

[0128] 2.8 Effect of CYP1-A on the Expression of Cleaved-Caspase-3, ZO-1 and Claudin-2 Proteins in Colonic Tissue

[0129] Weigh about 20 mg of colon tissue into a 1.5 mL centrifuge tube, add 5 times the amount of lysis solution (about 100 μL) (containing 1% protease inhibitor and 1% phosphatase inhibitor), and break the tissue with an automatic homogenizer at 4°C (the instrument parameters are 60mHZ, 1min, repeated 5 times), place on ice for 30 minutes, and centrifuge at 4°C, 10000rpm, for 15 minutes. Transfer the supernatant to a new 1.5 mL EP tube. Use Thermo Scientific BCA kit was used to determine the protein concentration. The protein sample was appropriately diluted according to the measured concentration. 5× loading buffer was denatured by boiling at 100℃ for 10min to prepare the loading protein. After electrophoresis, transfer, blocking, incubation with primary antibody, incubation with secondary antibody, ECL luminescence and other steps, the expression of Cleaved-Caspase-3, ZO-1 and Claudin-2 proteins was detected by Western blot. The dilution ratio of antibodies ZO-1, Claudin-2 and Cleaved-Caspase-3 was 1:1000. The transfer conditions were 250mA transfer for 100min or 150min (depending on the molecular weight of the protein). Image J software was used to analyze and process the protein bands.

[0130] The results are as follows Figure 17-18 shown.

[0131] like Fig.17 As shown in the figure, compared with the normal group, the expression of Cleaved-Caspase-3 protein in the DSS model group was significantly increased, and after CYP1-A treatment, the expression of Cleaved-Caspase-3 protein showed a downward trend. This indicates that CYP1-A can inhibit intestinal epithelial cell apoptosis to a certain extent by downregulating the expression of Cleaved-Caspase-3 protein induced by DSS.

[0132] like Fig.18 As shown in the figure, compared with the normal group, the expression of Claudin-2 in the model group was significantly increased (P<0.05), and the expression of Claudin-2 in the DSS+CYP1-A group was significantly decreased compared with the DSS group, with statistical difference (P<0.01). This indicates that CYP1-A can downregulate the expression of Claudin-2 protein induced by DSS. The expression of ZO-1 was significantly decreased in the model group (P<0.001), and after CYP1-A treatment, ZO-1 protein was significantly upregulated (P<0.01).

[0133] Experimental Example 3: Immunomodulatory effect of CYP1-A

[0134] During the experiment, IBM SPSS 20.0 statistical software and GraphPad Prism 8.0.2 software were used to analyze the data and draw statistical graphs. Data are presented as mean ± standard deviation If the data obeyed the normal distribution and variance homogeneity, one-way analysis of variance was used, and Bonferroni test was used for multiple comparisons; if the data did not meet the variance homogeneity, Dunnett'3T3 test was used for statistical analysis. All tests were two-sided, and P < 0.05 indicated statistical significance.

[0135] 3.1 Cell culture

[0136] RAW 264.7 cells were cultured in complete medium containing 10% FBS (containing 1% double antibody) at 37°C and 5% CO. 2 Culture in an incubator and subculture every day at a ratio of 1:3. When the cell confluence of the culture dish reaches 80%, pour out the culture medium, rinse twice with PBS, add 2mL of trypsin (2mL for 100mm culture dish and 1mL for 60mm culture dish) to moisten the bottom of the culture dish, digest in the incubator for 30s, and terminate the digestion with 4mL of complete culture medium. Use a pipette to gently blow the cells to make them fall off, and transfer them to a new 15mL centrifuge tube. Centrifuge at 800rpm for 4min, pour out the supernatant, and keep the cells at the bottom of the tube. Then, resuspend the cells and transfer them to a culture dish containing fresh complete culture medium for continued cultivation.

[0137] 3.2 MTT assay for cell viability

[0138] Cells in the logarithmic growth phase were seeded in 96-well plates (20,000 cells / well). After RAW 264.7 cells adhered to the plate for 12 hours, the culture medium was removed and 100 μL of complete culture medium containing yam polysaccharides (CYP, CYP2 and CYP1-A) was added to each well of the drug-treated group. The final concentration of yam polysaccharides was 400 μg mL -1 The control group was a complete medium without any drugs. The culture was continued in the incubator for 24 hours. The culture medium was aspirated with a spray gun, and 100 μL of MTT solution was added. The cells were incubated in the incubator for 4 hours. The MTT solution was then aspirated and 250 μL of DMSO reagent was added to each well. The cells were shaken on a plate shaker for 10 minutes. The purple crystals were observed to dissolve and disappear under a microscope. The cells were then placed in an ELISA reader and the absorbance of each well was detected at 570 nm.

[0139] The cell survival rate of the control group was defined as 100%, and the ordinate indicated the percentage (%) of the change in the drug group compared with the control group. Fig.19 As shown, yam polysaccharide CYP and CYP1-A had no effect on the activity of RAW 264.7 cells at a concentration of 400 μg / mL.

[0140] 3.3 NO detection

[0141] RAW 264.7 cells were seeded in 6-well plates (1 million / well), adhered for 12 hours, and 400 μg / mL yam polysaccharide was administered and incubated for 24 hours, and then the cell supernatant was collected. Based on the Griess reaction, the NO content in the cell supernatant was determined using a NO detection kit. 50 μL of cell culture supernatant, 100 μL of Griess reagent I, and 100 μL of Griess reagent II were added to a 96-well plate in sequence, and the absorbance was detected by an ELISA instrument at a wavelength of 540 nm.

[0142] Taking the NO content of the control group as the benchmark, the ordinate represents the multiple of the change in the drug group compared with the control group. The results are as follows Fig. 20 As shown in the figure, CYP1-A can significantly promote the secretion of NO in RAW 264.7 cells (P<0.01, compared with the control group). The NO secretion level in the CYP group increased slightly, but there was no statistical difference (P>0.05).

[0143] 3.4. ELISA kits to detect the content of TNF-ɑ and IL-6 in the culture medium of RAW 264.7 cells RAW 264.7 cells were seeded in 12-well plates (500,000 / well) and cultured in an incubator for 12 hours. After 24 hours of intervention with yam polysaccharide, the cell supernatant was collected. TNF-ɑ and IL-6 kits were used to detect the levels of related cytokines in the cell culture medium.

[0144] The results are as follows Fig.21 As shown in the results, the contents of IL-6 and TNF-ɑ increased significantly in the culture supernatant of RAW 264.7 cells, indicating that CYP1-A can significantly promote the secretion of IL-6 and TNF-ɑ (P<0.001). However, yam polysaccharide CYP had no effect on the secretion levels of IL-6 and TNF-ɑ (P>0.05).

[0145] 3.5. PCR detection of IL-6, TNF-ɑ, IL-1β, and iNOS gene expression in cells

[0146] RAW 264.7 cells were seeded in 12-well plates (500,000 / well). After adhesion and drug incubation, the culture dish was taken out of the incubator and placed on ice. The cells were rinsed three times with 1 mL of pre-cooled PBS and fully lysed by adding 250 μL of Trizon reagent. Total cell RNA was then extracted and purified. Reverse transcription was performed using the Evo M-MLV Reverse Transcription Kit II and amplification was performed using the Perfect Start Greenq PCR Super Mix Kit. After the amplification reaction was completed, the internal reference gene GAPDH was used as the reference and 2 -ΔΔCTThe relative expression fold of the target gene was calculated by the method. The primer sequences of IL-6, TNF-ɑ, IL-1β and internal reference are the same as those in Table 4. iNOS primer sequence (5'→3'):

[0147] Forward:ACTCAGCCAAGCCCTCACCTAC;

[0148] Reverse:TCCAATCTCTGCCTATCCGTCTCG.

[0149] The experimental results are as follows Fig. 22 As shown in the data, after CYP1-A acted on RAW 264.7 cells, the expression of IL-6, TNF-ɑ, IL-1β, and iNOS genes were significantly increased. After CYP treatment, there was no effect on the expression of TNF-ɑ, IL-1β, and iNOS mRNA (P>0.05), but the expression of IL-6 was significantly upregulated (P<0.001).

[0150] 3.6. Western blot detection of cell p-p65 protein expression

[0151] RAW 264.7 cells were seeded in 6-well plates (1 million / well). After 6 hours of yam polysaccharide administration, the culture plates were taken out of the incubator and placed on ice. The cells were rinsed 3 times with 1 mL of pre-cooled PBS, and 50-80 μL of lysis buffer (containing 1% protease inhibitor and 1% phosphatase inhibitor) was added to fully lyse the cells, extract cell proteins, and then the expression level of p-p65 protein was detected by Western blot. The protein loading amount was 3 μg. Image J software was used to analyze and process the protein bands.

[0152] NF-κB is an important transcriptional regulator that plays a vital role in cellular immune response. After RAW 264.7 cells were treated with yam polysaccharide, the expression level of p-p65 protein was detected by Western blot. Fig.23 As shown in the results, CYP1-A could significantly upregulate the expression of p-p65 protein (P<0.05), but CYP polysaccharide had no effect on the expression of p-p65 protein (P>0.05), which indicated that CYP1-A enhanced the immune function of RAW 264.7 cells by activating the NF-κB pathway.

[0153] The above are only some embodiments of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the creative concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. A method for preparing yam α-glucan, characterized in that: The steps include: S1: Pretreatment: Degreasing, depigmenting and deproteinizing crude yam polysaccharide, dialyzing the obtained polysaccharide aqueous solution, and drying to obtain yam polysaccharide; S2: Anion exchange column chromatography separation: The yam polysaccharide is prepared into a yam polysaccharide aqueous solution, and then separated by anion exchange column, and the eluate obtained by eluting with ultrapure water is collected and dried to obtain yam secondary polysaccharides; S3: Gel column chromatography purification: The yam secondary polysaccharide is prepared into a yam secondary polysaccharide aqueous solution, and then separated using a Superdex200prep grade gel column and eluted with ultrapure water. During the elution process, the molecular weight of the sugar in the eluate is tracked and detected, and the eluate with a molecular weight of 5000-25000Da is collected and dried to obtain yam α-glucan.

2. The preparation method according to claim 1, characterized in that: In step S1, the degreasing, depigmenting and deproteinizing treatment of crude yam polysaccharide comprises the following steps: (1) Extracting crude yam polysaccharide with a solvent obtained by mixing methanol and chloroform in a volume ratio of 8:1 at 80° C. and reflux extracting for 24 hours, removing the solvent, and drying to obtain crude yam polysaccharide I; the solid-liquid ratio of crude yam polysaccharide to solvent is 1:(5-12) g / mL; (2) extracting the yam crude polysaccharide I with ethanol having a mass fraction of not less than 95% by reflux for 3 times, each time for 60 minutes, removing the ethanol, and drying to obtain the yam crude polysaccharide II; the solid-liquid ratio of the yam crude polysaccharide I to ethanol is 1:10 g / mL; (3) The crude yam polysaccharide II was prepared into a 50 mg / mL aqueous solution, and a mixture of chloroform and n-butanol in a volume ratio of 4:1 was added in a volume ratio of 5:

1. After mixing, the upper layer of the polysaccharide aqueous solution was centrifuged and the above steps were repeated until the protein layer was no longer obvious.

3. The preparation method according to claim 2, characterized in that: In step S1, in the dialysis treatment, the molecular weight cut-off is 3500Da.

4. The preparation method according to any one of claims 1 to 3, characterized in that In step S2, the concentration of the yam polysaccharide aqueous solution is 100-150 mg / mL; in step S3, the concentration of the yam secondary polysaccharide aqueous solution is 50-100 mg / mL.

5. The preparation method according to claim 4, characterized in that: The anion exchange column is DEAE Sephadex Fast Flow.

6. The preparation method according to claim 5, characterized in that: The method for tracking and detecting the molecular weight of the sugar in the eluent during the elution process is selected from one of the phenol-sulfuric acid method and the high performance gel permeation chromatography method.

7. The preparation method according to claim 6, characterized in that: During the elution process, the TM The molecular weight of the sugars in the eluate was tracked and detected using a SEC-150 gel chromatography column.

8. Yam α-glucan obtained according to the preparation method according to any one of claims 1 to 7.

9. A pharmaceutical composition, characterized in that The invention comprises the yam α-glucan as claimed in claim 8 and one or more pharmaceutically acceptable auxiliary materials.

10. Use of the yam α-glucan according to claim 8 or the pharmaceutical composition according to claim 9 in the preparation of a medicament for treating ulcerative colitis.